Biotech Stocks : Top Stocks Celldex Therapeutics Inc (NASDAQ CLDX) & Dyax Corp. (NASDAQ DYAX)

Biotech stock market news

Here in this article, we take a look at two very promising Biotech stock: Celldex Therapeutics Inc (NASDAQ CLDX) & Dyax Corp (NASDAQ DYAX). Dyax Corp (NASDAQ DYAX) has had the stock price surge after the company made some major announcements in the past couple of months. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is hoping for similar fortunes, with the stock targeting a positive upside in the coming weeks.

Dyax Corp. (NASDAQ:DYAX)announced dosing of the first subject in its Phase 1b clinical study of DX-2930 in hereditary angioedema (HAE) patients. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of multiple subcutaneous administrations of DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) recently reported data from its ongoing Phase 1 study of the fully human monoclonal antibody varlilumab (CDX-1127) in cancer. Varlilumab is an immunotherapy designed to enhance the body’s natural immune response by directly activating T cells that can specifically recognize and kill cancer cells. Preclinical data support the broad study of varlilumab in combination with a number of other anti-cancer agents including but not limited to checkpoint inhibitors, chemotherapies, targeted therapies and vaccines.

Celldex Therapeutics Inc (NASDAQ CLDX) & Dyax Corp. (NASDAQ DYAX)

Varlilumab will enter at least four combination studies in the second half of 2014. Celldex has done some very good research work related with Varlilumab. This year Company’s Earnings per Share (EPS) growth is 3.50% and next year’s estimated EPS growth is -1.45. Analysts mean target price for Celldex Therapeutics, Inc. (NASDAQ:CLDX) is $35.50.

Dyax, a biopharmaceutical company focused on HAE and other plasma-kallikrein-mediated disorders, is developing DX-2930 as a subcutaneous injection for prevention of HAE attacks. Dyax Corp. (NASDAQ:DYAX) belongs to Healthcare sector with market capitalization of 1.17 billion and has 0.60% insider ownership.

Celldex Therapeutics Inc (NASDAQ CLDX) & Dyax Corp. (NASDAQ DYAX) News Video

Watch this video for more “Celldex Therapeutics Inc (NASDAQ CLDX) & Dyax Corp. (NASDAQ DYAX)” news.

Celldex Therapeutics Inc (NASDAQ CLDX) & Dyax Corp. (NASDAQ DYAX) Financial News

Both Celldex Therapeutics Inc (NASDAQ CLDX) & Dyax Corp. (NASDAQ DYAX) seem to be in for a good run in the coming months. The research work done by them has given some positive results. Whether the stocks actually rise to the expected levels, remains to be seen.

Thanks for visiting the TechNews.org website. Be sure to catch all BioTech financial news, bookmark us and check all the videos and news articles regarding Biotech business news.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone